Nuclidium raises €84m in Series B funding to accelerate radiopharmaceutical development

Nuclidium has secured €84m in a Series B funding round led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR. Additional participation came from a broad syndicate including DeepTech and Climate Fonds, Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, HighLight Capital, and existing backers. The Swiss biotech venture will deploy the capital to accelerate the development of its lead radiopharmaceutical compounds and widen its manufacturing footprint across international markets.

The company focuses on proprietary platforms utilising Copper-61 for PET imaging and Copper-67 for targeted radiotherapy. These assets aim to enhance therapeutic precision for challenging oncological indications such as metastatic prostate cancer, neuroendocrine tumours, and breast cancer. The fresh injection will also support the expansion of its clinical team and deepen ongoing research collaborations with academic hospitals in Europe and North America.